Pruritus Therapeutics Global Market Report 2024

The pruritus therapeutics market size has grown strongly in recent years. It will grow from $11.39 billion in 2023 to $12.03 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The increase observed during the historical period can be ascribed to a rise in the incidence of pruritus, a variety of causes and conditions, the growing aging population, and a heightened focus on improving patient quality of life.

The pruritus therapeutics market size is expected to see strong growth in the next few years. It will grow to $14.99 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The expansion projected for the forecast period can be linked to the broader understanding of pruritus pathophysiology, advancements in drug formulations and delivery methods, a spotlight on personalized medicine, a surge in dermatological research and development, heightened awareness and diagnosis rates, and an increasing interest in botanical and herbal remedies. Noteworthy trends anticipated during the forecast period encompass the development of itch-specific receptor agonists and antagonists, a market emphasis on personalized therapeutic approaches, the integration of technology in itch monitoring and management, and collaborative efforts for cross-disciplinary research.

The pruritus therapeutics market is anticipated to witness growth due to the increasing incidence of dermatological disorders. Dermatological disorders encompass a range of conditions affecting the skin, hair, nails, and mucous membranes, including acne, eczema, skin cancer, and fungal infections. The use of pruritus treatments is often determined by the underlying cause of itching, involving topical treatments, emollients, immunosuppressant medications, and specific itching medications. A report by the American Cancer Society Inc. revealed a 5.8% increase in skin cancer cases from 2020 to 2021, reaching 108,480 cases. This surge in dermatological disorders is a driving force behind the growth of the pruritus therapeutics market.

The global increase in the geriatric population is expected to contribute to the expansion of the ocular implant market. The geriatric population, comprising individuals aged 65 and older, is more susceptible to pruritus due to various factors associated with aging. According to the World Health Organization, the global population of individuals aged 60 and above is projected to reach 1.4 billion by 2022, compared to 1 billion in 2020. The aging population's specific needs make pruritus therapeutics crucial in addressing itching concerns. The rise in the geriatric population worldwide is poised to drive the growth of the pruritus therapeutics market. Notably, Ipsen, a France-based biopharmaceutical company, collaborated with Medison Pharma in November 2023 to develop an innovative pruritus treatment, Bylvay, for patients aged 6 months or older with Progressive Familial Intrahepatic Cholestasis (PFIC).

A prominent trend in the pruritus therapeutics market is product innovation, with major companies focusing on developing novel treatments to strengthen their market position. For instance, in August 2021, Fresenius Medical Care AG & Co., a Germany-based provider for people with kidney illnesses, launched KORSUVA (difelikefalin) for reducing pruritus related to chronic kidney dysfunction in adults undergoing hemodialysis. This therapeutic injectable drug, approved by the FDA, is a first-in-class kappa opioid receptor (KOR) targeting the outer neurological system. Product innovation remains a key strategy for companies aiming to enhance the safety and effectiveness of pruritus treatments.

Leading companies in the pruritus therapeutics market are concentrating on the development of oral solutions for managing cholestatic pruritus in patients with Alagille syndrome (ALGS) aged one year and older. An oral solution for cholestatic pruritus is a liquid medication designed to alleviate itching associated with liver conditions. In September 2021, Mirum Pharmaceuticals, Inc., a US-based biotechnology company, received FDA approval for LIVMARLI (maralixibat) oral solution to manage cholestatic pruritus in individuals aged one year and older with ALGS. The company's Mirum Access Plus (MAP) program provides access to LIVMARLI, offering support services, insurance coverage, and financial assistance through dedicated coordinators.

In March 2023, Ipsen, the France-based biopharmaceutical company, acquired Albireo Pharma, Inc., a US-based clinical-stage biopharmaceutical company. This strategic acquisition aims to expand Ipsen's portfolio by incorporating promising medicines for pediatric and adult uncommon cholestatic liver disorders. Albireo Pharma, Inc., specializes in oral drugs, including the first treatment for pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). The acquisition enriches Ipsen's capabilities with unique pipeline potential and scientific and commercial expertise.

Major companies operating in the pruritus therapeutics market report are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, Eli Lilly and Company, Amgen Inc. , Regeneron Pharmaceuticals Inc., Astellas Pharma Inc. , Bausch Health Companies Inc., Brunswick Corporation, Galderma Laboratories LP, Cipla Limited, Vifor Pharma Ltd., Carl Zeiss Meditec AG, LEO Pharma AS, Mirum Pharmaceuticals Inc., Cara Therapeutics Inc., GlaxoSmithKline PLC, Novan Inc., Escient Pharmaceuticals Inc., Nerre Therapeutic Ltd., EPI Health LLC, Trevi Therapeutics Inc., Evelo Biosciences, Toray Medical Co. Ltd.

North America was the largest region in the pruritus treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pruritus therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary product categories of pruritus therapeutics encompass corticosteroids, antihistamines, local anesthetics, counterirritants, immunosuppressants, calcineurin inhibitors, and others. Corticosteroids denote synthetic anti-inflammatory medications utilized to address itching and inflammation resulting from pruritus. These medications can be administered through various routes, including oral, parenteral, and topical, aiding in the treatment of diverse disease types such as atopic dermatitis, allergic contact dermatitis, urticaria, cutaneous T-cell, among others. They find application in hospitals, clinics, and other medical settings.

The pruritus therapeutics research market report is one of a series of new reports that provides pruritus therapeutics market statistics, including pruritus therapeutics industry global market size, regional shares, competitors with a pruritus therapeutics market share, detailed pruritus therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the pruritus therapeutics industry. This pruritus therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pruritus therapeutics market consists of revenues earned by entities by providing topical therapy, phototherapy, and systemic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The pruritus therapeutics market also include sales of hydroxyzine, benadryl, banophen, diphedryl, and allermax. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.